Cullinan Therapeutics has dosed the first patient in its Phase 2 study of CLN-049, an investigational T cell engager targeting FLT3 in relapsed or refractory acute myeloid leukemia (AML). This study aims to evaluate CLN-049's safety and efficacy in patients who have had up to two prior therapies, including a cohort for newly diagnosed TP53-mutated AML. CLN-049 offers a novel immunotherapy approach for AML, a disease with limited treatment options and poor outcomes, especially in relapsed cases. Updates from ongoing Phase 1 studies and combination trials with azacitidine and venetoclax are expected later this year.
Cullinan Therapeutics' new Phase 2 study dosing is noted alongside Pluang's Health sector data as of Oct 08, 2026 18:11 WIB. Of 100 priced Health-sector US stocks tradable on Pluang, 25 rose and 68 fell today. Key movers include RXRX at USD 4.15 with a 1-day change of -2.81% and 95% sell order activity, HRTX at USD 0.38 with a 1-day change of -2.56% and 70% buy order activity, and TWST at USD 151.90 with a 1-day change of -2.41% and 97% buy order activity.
Dividend 15 Split Corp. has renewed its at-the-market (ATM) equity program, allowing it to issue shares to the public at prevailing market prices until November 7, 2028. This program replaces the previous one that ended in 2025 and enables the compan...
Fieldstone Bio, a synthetic biology company, was selected for the Mining Tech Accelerator program by Founders Factory and Rio Tinto. The program supports innovative technologies that improve mineral exploration and extraction, providing Fieldstone wi...
Beam Global has signed a definitive agreement to acquire ScoutDI, a company specializing in drone technology and AI-powered inspection software. The acquisition will enable Beam to manufacture ScoutDI's drone systems in the US and Europe, targeting i...
Grabar Law Office is investigating shareholder claims against four companies—Aardvark Therapeutics, Coastal Financial Corporation, Erasca, Inc., and New Era Energy & Digital—for alleged securities violations and breaches of fiduciary duties. The clai...
Visa Canada's data reveals that the Toronto International Film Festival (TIFF) 2026 increased visitor spending by 12% compared to 2025, with international visitors spending about 40% more than Canadian cardholders. The festival attracted visitors mai...
